A Phase 2, Multi-centre, Open-label, Study to Evaluate the Efficacy and Safety of WTX101 Administered for 24 Weeks in Newly Diagnosed Wilson Disease Patients Aged 18 and Older With an Extension Phase of 12 Months

Trial Profile

A Phase 2, Multi-centre, Open-label, Study to Evaluate the Efficacy and Safety of WTX101 Administered for 24 Weeks in Newly Diagnosed Wilson Disease Patients Aged 18 and Older With an Extension Phase of 12 Months

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Bis-choline tetrathiomolybdate (Primary)
  • Indications Hepatolenticular degeneration
  • Focus Therapeutic Use
  • Sponsors Wilson Therapeutics
  • Most Recent Events

    • 12 Apr 2018 Results of preliminary long-term data at week 72 presented in a Wilson Therapeutics Media Release.
    • 12 Apr 2018 According to the Wilson Therapeutics media release, data from extension part of this study (at week-72) will be presented at the The International Liver Congress™ 2018, the Annual Meeting of the European Association for the Study of the Liver (EASL).
    • 23 Feb 2018 According to According to the Wilson Therapeutics media release, 12 month extension phase study is ongoing. Hence status of the study is kept as active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top